Month: June 2022

FREMONT, Calif., June 03, 2022 (GLOBE NEWSWIRE) — Aehr Test Systems (NASDAQ: AEHR), a worldwide supplier of semiconductor test and reliability qualification equipment, today announced that CEO and President Gayn Erickson will be presenting at the LD Micro 12th Annual Invitational Conference on Wednesday, June 8th at 12:00pm PT at the Four Seasons Hotel in Westlake Village, CA, and will be meeting with investors throughout the day. You may register to watch the presentation here. “We look forward to discussing our semiconductor wafer level and singulated die test and burn-in solutions and the markets they serve with investors,” said Mr. Erickson. “Aehr Test provides complete production solutions for improving yield and reliability of semiconductors, and devices such as silicon carbide semiconductors used in electric and hybrid electric...

BOSTON, June 03, 2022 (GLOBE NEWSWIRE) — Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that John Lee, chief development officer, and Lis Leiderman, M.D., MBA, chief financial officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Friday, June 10, 2022 at 9:00 a.m. ET. A live webcast of the fireside chat may be accessed by visiting the Investors section of the Decibel Therapeutics website at https://ir.decibeltx.com. An archived replay of the webcast will be available on the Company’s website for approximately 90 days following the fireside chat. About Decibel Therapeutics Decibel Therapeutics is a clinical-stage biotechnology company dedicated...

MONTREAL, June 03, 2022 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (TSX: GUD) (“Knight”) a pan-America (ex-USA) specialty pharmaceutical company, announced today that Samira Sakhia, President and Chief Executive Officer, is scheduled to present at the Jefferies 2022 Healthcare Conference on Friday, June 10, 2022 at 10:00 AM ET in New York City. A copy of the presentation will be available at www.gud-knight.com. About Knight Therapeutics Inc. Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. Knight’s Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics Inc.’s shares trade on TSX under...

COBALT study in advanced PBC, previously terminated early due to feasibility challenges, did not demonstrate a statistically significant difference in clinical endpoints between Ocaliva® and placebo HEROES-US real-world analysis demonstrated statistically significant improvement in event-free survival in patients receiving Ocaliva for PBC Intercept plans to include these data in an evidence package that will be submitted to U.S. FDA in 2H 2022 to support post-marketing regulatory requirements MORRISTOWN, N.J., June 03, 2022 (GLOBE NEWSWIRE) — Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral liver diseases, today announced results from two studies designed to evaluate clinical outcomes in patients with PBC on Ocaliva...

LONDON and AMSTERDAM, June 03, 2022 (GLOBE NEWSWIRE) — Blockmate Ventures Inc. (TSX.V: MATE) (FSE: 8MH1) (“Blockmate” or the “Company”) has uploaded a recording of the online investor briefing held on June 2nd, 2022 to its website, featuring an update from Blockmate CEO & President Dom Carosa. The recording can be viewed here: https://www.blockmate.com/videos The Investor deck can be download here: https://bit.ly/Blockmate-Deck-2June2022 The briefing included updates for investors on:Blockmate’s blockchain incubation vision and successful track record of projects The Hivello revenue model and regional targets for IoT hotspots An updated strategy for Blockmate’s asset Midpoint with ways to maximise revenue A new consumer-focused de-fi (decentralized finance) platform – Yield OTCBlockmate welcomes investors...

BASEL, Switzerland, June 03, 2022 (GLOBE NEWSWIRE) — Myovant Sciences (NYSE: MYOV), a biopharmaceutical company that aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy, today announced that David Marek, Chief Executive Officer and Uneek Mehra, Chief Financial and Business Officer of Myovant Sciences, Inc., will participate in a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference on Thursday, June 16, 2022 at 11:00 a.m. Eastern Time. Investors and the general public are invited to listen to the Goldman Sachs fireside chat, which will be accessible on the Events page under the Investors & Media section of the Myovant website at www.myovant.com. ABOUT MYOVANT SCIENCESMyovant Sciences aspires to redefine care for women and for...

SÃO PAULO, Brazil, June 03, 2022 (GLOBE NEWSWIRE) — Vasta Platform Limited (NASDAQ: VSTA) announces the execution of a minority investment agreement by its wholly-owned subsidiary, Somos Sistemas de Ensino S.A. (“Somos”), which establishes the terms and conditions for the issuance and the payment of new shares on Educbank Gestão de Pagamentos Educacionais S.A. (“Educbank”). According to the agreement, the investment will be made in installments over a two-year period, upon subscription of new Educbank shares, according to the growth of students served by Educbank and other conditions. The closing of the transaction is subject to certain conditions precedent, including the approval by the Brazilian antitrust authority. Educbank is the first financial ecosystem dedicated to K-12 schools, intended to expand access to quality education...

CAMBRIDGE, Mass., June 03, 2022 (GLOBE NEWSWIRE) — Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer, will participate in a fireside chat during the 2022 Jefferies Healthcare Conference on Friday, June 10, 2022 at 9:30 a.m. ET in NYC. A live webcast will be available in the investor section of the company’s website at www.beamtx.com, and will be archived for 60 days following the presentation. About Beam TherapeuticsBeam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform that includes a suite of gene editing and delivery technologies and is...